Publication details
TYSABRI – nový management rizik
| Title in English | TYSABRI – new management of risk factors |
|---|---|
| Authors | |
| Year of publication | 2017 |
| Type | Article in Periodical |
| Magazine / Source | Neurologie pro praxi |
| MU Faculty or unit | |
| Citation | |
| Field | Neurology, neurosurgery, neurosciences |
| Keywords | natalizumab; monoclonal antibodies; multiple sclerosis; progressive multifocal leukoencephalopathy |
| Description | Natalizumab belongs to monoclonal antibodies. This is a high- efficacy drug, which substantially reduces the activity and leads to long-term stabilization of multiple sclerosis. However, the therapy is associated with a risk of developing progressive multifocal leukoencephalopathy (PML) in patients infected with the John Cunningham Virus. Standardized high-quality monitoring procedures, clinical assessments, magnetic resonance imaging monitoring and use of biomarkers enable risk stratification. Early detection of disease in asymptomatic stage substantially improves survival and reduce the functional outcomes. |